NCT06725758View on ClinicalTrials.gov

Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

315

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Solid Tumours

Interventions

DRUG

ODM-212

ODM-212 5mg and/or 40mg tablets

Trial Locations (1)

SW36JJ

RECRUITING

Royal Marsden Hospital, London, UK, London

All Listed Sponsors

lead

Orion Corporation, Orion Pharma

INDUSTRY